IRL757 & IRL942 to Ph 1 in YE'23e and H1'24e
Pirepemat PD-Falls trial readout delayed to H1'24e
IRLAB provided some updates on its portfolio development milestones. Due to slower than anticipated trial recruitment, the company announced that trial recruitment of the Ph 2b trial of pirepemat in Parkinson's disease falls (PD-Falls) is now expected by YE'23, with the subsequent data readout slightly delayed to H1'24 (YE'23). As of today, 28 out of 39 planned sites in five EU countries are active and recruiting.
LÄS MER
